The iminodipropionitrile (IDPN)-induced dyskinetic syndrome in mice: antagonism by the calcium channel antagonist nifedipine.
Chronic administration of IDPN leads to the development of a persistent syndrome which is characterized by lateral and vertical neck dyskinesias, random circling behaviors, and locomotor hyperactivity. Although the dihydropyridine (DHP) calcium channel antagonist nifedipine inhibited all aspects of the syndrome, lateral head dyskinesias (laterocollis) and circling abnormalities were the most significantly affected signs. Dysregulation of calcium-dependent processes might be involved in the pathogenesis of the IDPN-induced dyskinetic abnormalities and clinical disorders of movement in humans.
D000818:Animals; D001665:Binding Sites; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D004095:Dihydropyridines / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D005260:Female; D007473:Ion Channels / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D009543:Nifedipine / Q000494:pharmacology*; D009570:Nitriles / Q000037:antagonists & inhibitors* / Q000633:toxicity
D004095:Dihydropyridines; D007473:Ion Channels; D009570:Nitriles; C008110:3,3'-iminodipropionitrile; C038806:1,4-dihydropyridine; D009543:Nifedipine; D002118:Calcium